{"brief_title": "SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma", "brief_summary": "The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).", "condition": "Carcinoma, Renal Cell", "intervention_type": "Drug", "intervention_name": "SU011248", "description": "50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity", "arm_group_label": "1", "other_name": "Sunitinib, SUTENT", "criteria": "Inclusion Criteria: - Histologically confirmed renal cell carcinoma of clear cell histology with metastases - Evidence of measurable disease by radiographic technique - Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1 Exclusion Criteria: - Prior systemic (including adjuvant or neoadjuvant) therapy of any kind for RCC - History of or known brain metastases - Serious acute or chronic illness or recent history of significant cardiac abnormality", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00083889.xml"}